Regulatory FDA hands BeOne, Taiho approvals for blood cancers PharmaphorumBeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.HematologyRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaphorum BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho’s Inqovi has acute myeloid leukaemia added to its label. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Regulatory round-up: A month of key FDA approvals for cancer drugsNext: Regenxbio’s Duchenne gene therapy clears phase 3 hurdle Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
